Abstract
Ten patients with advanced progressive adenocarcinoma of the prostate were treated with a long acting analogue of gonadotrophin releasing hormone. Eight of these patients responded to treatment in terms of pain relief and clinical regression of tumour. Serum gonadotrophin and testosterone concentrations were significantly suppressed by the end of the second week of treatment, testosterone concentrations being comparable with those achieved by castration. The two patients who failed to respond had both relapsed previously when receiving conventional treatment, and neither showed any endocrine response to the analogue. Superagonists of gonadotrophin releasing hormone may be the treatment of choice in adenocarcinoma of the prostate, but further trials are required to establish long term safety and efficacy.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Borgmann V., Hardt W., Schmidt-Gollwitzer M., Adenauer H., Nagel R. Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach? Lancet. 1982 May 15;1(8281):1097–1099. doi: 10.1016/s0140-6736(82)92279-6. [DOI] [PubMed] [Google Scholar]
- Ghanadian R., Lewis J. G., Chisholm G. D. Serum testosterone and dihydrotestosterone changes with age in rat. Steroids. 1975 Jun;25(6):753–762. doi: 10.1016/0039-128x(75)90039-2. [DOI] [PubMed] [Google Scholar]
- Hutchison G. B. Incidence and etiology of prostate cancer. Urology. 1981 Mar;17(Suppl 3):4–10. [PubMed] [Google Scholar]
- Linde R., Doelle G. C., Alexander N., Kirchner F., Vale W., Rivier J., Rabin D. Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. N Engl J Med. 1981 Sep 17;305(12):663–667. doi: 10.1056/NEJM198109173051203. [DOI] [PubMed] [Google Scholar]
- Marshall J. C., Anderson D. C., Burke C. W., Galvao-Teles A., Fraser T. R. Clomiphene citrate in men: increase of cortisol, luteinizing hormone, testosterone and steroid-binding globulins. J Endocrinol. 1972 May;53(2):261–276. doi: 10.1677/joe.0.0530261. [DOI] [PubMed] [Google Scholar]
- Marshall J. C., Anderson D. C., Fraser T. R., Harsoulis P. Human luteinizing hormone in man: studies of metabolism and biological action. J Endocrinol. 1973 Mar;56(3):431–439. doi: 10.1677/joe.0.0560431. [DOI] [PubMed] [Google Scholar]
- Pinto H., Wajchenberg B. L., Lima F. B., Goldman J., Comaru-Schally A. M., Schally A. V. Evaluation of the gonadotrophic responsiveness of the pituitary to acute and prolonged administration of LH/FSH-releasing hormone (LH-RH) in normal females and males. Acta Endocrinol (Copenh) 1979 May;91(1):1–13. doi: 10.1530/acta.0.0910001. [DOI] [PubMed] [Google Scholar]
- Smith P. H., Akdas A., Mason M. K., Richards B., Robinson M. R., de Pauw M., Sylvester R. Hormone therapy in prostatic cancer. Acta Urol Belg. 1980 Jan;48(1):98–105. [PubMed] [Google Scholar]
- Tolis G., Ackman D., Stellos A., Mehta A., Labrie F., Fazekas A. T., Comaru-Schally A. M., Schally A. V. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A. 1982 Mar;79(5):1658–1662. doi: 10.1073/pnas.79.5.1658. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Whitehead E. D. Management of prostate carcinoma. N Y State J Med. 1981 Sep;81(10):1481–1485. [PubMed] [Google Scholar]
- Yen S. S., Tsai C. C., Naftolin F., Vandenberg G., Ajabor L. Pulsatile patterns of gonadotropin release in subjects with and without ovarian function. J Clin Endocrinol Metab. 1972 Apr;34(4):671–675. doi: 10.1210/jcem-34-4-671. [DOI] [PubMed] [Google Scholar]